BLAIV (INFUSION)POWDERPriority Review
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
EBANGA (ansuvimab) by Ridgeback Biotherapeutics is zaire ebolavirus glycoprotein-directed antibody interactions [moa]. Approved for zaire ebolavirus glycoprotein-directed antibody [epc]. First approved in 2020.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EBANGA (ansuvimab) is a monoclonal antibody directed against Zaire ebolavirus glycoprotein, approved for treatment of Zaire ebolavirus infection. It works by binding to the viral glycoprotein to neutralize the virus and facilitate immune clearance. This is a life-saving therapeutic for a rare but high-mortality infectious disease.
Peak
Peak-stage rare disease product with limited commercial scale; teams focus on outbreak preparedness, government procurement, and global health partnerships rather than high-volume primary care expansion.
Mechanism of Action
Zaire Ebolavirus Glycoprotein-directed Antibody Interactions
Pharmacologic Class:
Zaire Ebolavirus Glycoprotein-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
Ebola Virus Disease
Career Relevance
Working on EBANGA is a specialized, mission-driven career path focused on preparedness and global health rather than traditional commercial pharmaceutical development. This product offers unique exposure to government procurement, outbreak response operations, and international health policy, but limited scale for traditional sales and marketing roles.
Regulatory Affairs Specialist
Worked on EBANGA at Ridgeback Biotherapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.